ICRM
ABMD

Insight Capital Research & Management’s Abiomed Inc ABMD Stock Holding History

Insight Capital Research & Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,896
Closed -$1.27M – 145
2017
Q2 		$1.27M Buy
+8,896
New +$1.2M 0.75% 60
2016
Q4 		– Sell
-19,821
Closed -$2.55M – 142
2016
Q3 		$2.55M Buy
+19,821
New +$2.37M 1.13% 40
2015
Q4 		– Sell
-55,724
Closed -$5.17M – 118
2015
Q3 		$5.17M Buy
+55,724
New +$4.91M 1.56% 20

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Insight Capital Research & Management's ABMD Position: Q3 2017 in Review

Insight Capital Research & Management sold out of Abiomed Inc (ABMD) in Q3 2017, closing a stake of 8,896 shares — an estimated $1.27M sold.

Insight Capital Research & Management first reported a position in ABMD in Q3 2015 and held it in 3 quarters. The position peaked at $5.17M in Q3 2015. 318 funds tracked by Wall St. Rank hold ABMD as of Q3 2017.

  • Insight Capital Research & Management reported no remaining Abiomed Inc position as of Q3 2017 after selling out during the quarter.
  • Insight Capital Research & Management sold 8,896 Abiomed Inc shares in Q3 2017, an estimated $1.27M.
  • Insight Capital Research & Management first reported a position in Abiomed Inc in Q3 2015 and held it in 3 quarters.
  • Insight Capital Research & Management's Abiomed Inc position peaked at $5.17M in Q3 2015.
  • 318 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2017.

Based on Insight Capital Research & Management's 13F filing for Q3 2017, filed 15 Nov 2017.